Cardinal Health CEO Sells $29 Million in Stock After Earnings Send Shares to Record
CEO Jason Hollar leads a wave of insider selling that saw top executives liquidate nearly $60 million worth of company stock.
Yahoo13 days agoCAH
What Is Drawing Attention To Cardinal Health (CAH) Today?
Cardinal Health earnings and capital return in focus Cardinal Health (CAH) has drawn fresh attention after releasing its fourth quarter and full year 2026 results, paired with a new US$5b share repurchase authorization and a confirmed quarterly dividend. The latest numbers give you an updated view of how the healthcare distributor is converting its large revenue base into profit and cash flow. They also show how management is choosing to return capital to shareholders through buybacks and...
Yahoo15 days agoCAH
RBC Capital Initiates Coverage of Cardinal Health (CAH) with Outperform Recommendation
Fintel15 days agoCAH
Cardinal Health’s (CAH) Big Earnings Beat Hides a More Complicated Story
On August 11, Cardinal Health (NYSE:CAH) reported fourth-quarter fiscal 2026 results that on the surface look almost too good to be true. Non-GAAP diluted EPS jumped 40% year over year to $2.91, and full-year adjusted free cash flow hit $5 billion. But a large piece of that quarterly jump came from a one-time tariff refund, […]
Yahoo16 days agoCAH
Cardinal Health's Integration of Higher-Margin Services Will Drive Outperformance, RBC Says
Cardinal Health's (CAH) vertical integration of "higher-growth and higher-margin services" will comp
Yahoo16 days agoCAH
RBC Capital Initiates Coverage On Cardinal Health with Outperform Rating, Announces Price Target of $276
RBC Capital analyst Ryan Halsted initiates coverage on Cardinal Health (NYSE:CAH) with a Outperform rating and announces Price Target of $276.
Benzinga16 days agoCAH
Cardinal Health: Precision Medicine Drives A Sustained Revenue Growth Path
SeekingAlpha16 days agoCAH
1 S&P 500 Stock Worth Investigating and 2 We Turn Down
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Yahoo19 days agoCAH
AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
Bristol-Myers Squibb trades at less than half the valuation multiple of AbbVie, but AbbVie's revenue growth tells a different story about future earnings power.
Yahoo20 days agoCAH
Cardinal Health CEO details M&A strategy and growth
Jason Hollar, Cardinal Health (CAH) CEO joins Yahoo Finance Executive Editor Brian Sozzi to detail how M&A strategy, specialty pharma growth, and drug volume dynamics are driving profits.
Yahoo20 days agoCAH
Reasons to Hold Hinge Health Stock in Your Portfolio for Now
HNGE's strong revenue growth, raised 2026 outlook and expansion into Migraine and GI care support its growth prospects despite investment pressures.
Yahoo21 days agoCAH
SOLV Plans Health Information Systems Business Spinoff to Drive Growth
Solventum plans to spin off its $1.4B HIS business, sharpening its MedTech focus while giving HIS more flexibility to pursue growth.
Yahoo21 days agoCAH
Did New 7UP Formula, Dr Pepper Shakes and Board Addition Just Shift Keurig Dr Pepper's (KDP) Investment Narrative?
Keurig Dr Pepper has recently reported second-quarter 2026 results showing sales of US$7.31 billion and net income of US$142 million, while rolling out a lime-led reformulation of 7UP and partnering with Portillo’s on limited-time Dr Pepper shakes in the U.S. Alongside these product moves, the company has added Cardinal Health CFO Aaron Alt to its board as it works through a planned split into separate beverage and coffee businesses. With Aaron Alt joining the board during Keurig Dr Pepper’s...
Yahoo21 days agoCAH
Cardinal Health Stock Hits a Record High After Earnings: Is CAH Still a Buy?
Cardinal Health (CAH) gave investors plenty to like in its fiscal fourth-quarter report this week, sending shares to a record high of $258 as Wall Street digests another earnings beat and an encouraging FY27 outlook.
Yahoo21 days agoCAH
Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs
RVTY launches SuperFlex, a compact automated prenatal screening system aimed at expanding rapid in-house testing for smaller labs and clinics.
Yahoo22 days agoCAH
Can BWX Technologies' Nuclear Medicine Expansion Boost Growth?
BWXT expands its commercial nuclear portfolio through nuclear medicine, isotope production and radiopharmaceutical capabilities.
Yahoo22 days agoCAH
TD Cowen Maintains Buy on Cardinal Health, Raises Price Target to $280
TD Cowen analyst Charles Rhyee maintains Cardinal Health (NYSE:CAH) with a Buy and raises the price target from $275 to $280.
Benzinga22 days agoCAH
JP Morgan Maintains Neutral on Cardinal Health, Raises Price Target to $260
JP Morgan analyst Lisa Gill maintains Cardinal Health (NYSE:CAH) with a Neutral and raises the price target from $215 to $260.
Benzinga22 days agoCAH
Barclays Maintains Overweight on Cardinal Health, Raises Price Target to $275
Barclays analyst Glen Santangelo maintains Cardinal Health (NYSE:CAH) with a Overweight and raises the price target from $258 to $275.
Benzinga22 days agoCAH